The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

被引:117
|
作者
Caussy, Cyrielle [1 ]
Aubin, Adrien [1 ]
Loomba, Rohit [2 ,3 ,4 ]
机构
[1] Hosp Civils Lyon, Dept Endocrinol Diabete & Nutr, Hop Lyon Sud, F-69495 Pierre Benite, France
[2] Univ Calif San Diego, Dept Med, NAFLD Res Ctr, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA 92093 USA
关键词
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Type; 2; diabetes; Fibrosis; Cirrhosis; Cardiovascular disease; Insulin resistance; Metabolic syndrome; FATTY LIVER-DISEASE; LOW-DENSITY LIPOPROTEINS; CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; TRIMETHYLAMINE-N-OXIDE; ADVANCED FIBROSIS; GUT MICROBIOME; VASCULAR COMPLICATIONS; INSULIN-RESISTANCE; GLYCEMIC CONTROL;
D O I
10.1007/s11892-021-01383-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of Review Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are strongly associated. Both also associate with an increased risk of cardiovascular disease (CVD). Recent Findings Several studies have provided evidence that NAFLD could be an independent CVD risk factor. Given the strong association between NAFLD and T2DM, assessing the independent CV effect of these two conditions remains challenging. However, patients with T2DM and NAFLD exhibit higher risk of CVD compared with T2DM without NAFLD suggesting a potential synergistic increase of CV risk in patients with both T2DM and NAFLD supported by several shared pathophysiological pathways. Several anti-diabetic therapies have shown beneficial effect on both NAFLD and CVD. Patients with T2DM and NAFLD should be considered at high risk of CVD and could benefit from more intensive CV prevention. Additional long-term follow-up is needed to demonstrate that the treatment of NAFLD effectively reduces the risk of CVD.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Relationship Between Acylcarnitine and the Risk of Retinopathy in Type 2 Diabetes Mellitus
    Wang, Wan-Ying
    Liu, Xu
    Gao, Xiao-Qian
    Li, Xin
    Fang, Zhong-Ze
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [32] The bidirectional relationship between NAFLD and type 2 diabetes: A prospective population-based cohort study
    Wang, Minzhen
    Zhao, Yanan
    He, Yingqian
    Zhang, Lulu
    Liu, Jing
    Zheng, Shan
    Bai, Yana
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2023, 33 (08) : 1521 - 1528
  • [33] Assessment of Relationship Between Cardiovascular Risk and Risk of Development of Diabetes Mellitus
    Mamedov, M. N.
    Korneeva, M. N.
    Oynotkinova, O. Sh
    [J]. KARDIOLOGIYA, 2017, 57 (02) : 46 - 51
  • [34] Type 2 diabetes and cardiovascular risk factors
    Sharma, Morali D.
    Farmer, John Alan
    Garber, Alan
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 : 1 - 5
  • [35] Cardiovascular risk in patients with type 2 diabetes
    Parmar, M
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (09) : 1160 - 1160
  • [36] Reducing cardiovascular risk in type 2 diabetes
    Solomon, CG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05): : 457 - 459
  • [37] Type 2 Diabetes and Cardiovascular Risk in Women
    Russo, Giuseppina T.
    Baggio, Giovannella
    Rossi, Maria Chiara
    Kautzky-Willer, Alexandra
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [38] Adiponectin, type 2 diabetes and cardiovascular risk
    Lindberg, Soren
    Jensen, Jan Skov
    Bjerre, Mette
    Pedersen, Sune H.
    Frystyk, Jan
    Flyvbjerg, Allan
    Galatius, Soren
    Jeppesen, Jorgen
    Mogelvang, Rasmus
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (03) : 276 - 283
  • [39] A cardiovascular risk calculator for type 2 diabetes
    Coleman, RL
    Stevens, RJ
    Matthews, DR
    Holman, RR
    [J]. DIABETES, 2005, 54 : A172 - A172
  • [40] Hypoglycaemia and cardiovascular Risk in Type 2 Diabetes
    Kahl, S.
    [J]. DIABETOLOGE, 2021, 17 (08): : 822 - 824